This was the stock's third consecutive day of losses.
US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...
TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...
Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.
Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...
Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $91.41 which represents a decrease of $-0.47 or -0.51% from the prior close of $91.88. The stock opened at $92.19 and touched a low of ...
CWA Asset Management Group LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.5% in ...
GS-2121 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...
The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...